Studies have shown that subjects with psoriasis (PsO) are associated with an increased risk of developing metabolic syndrome (MetS), diabetes, and cardiovascular disease. In addition, MetS and diabetes are associated with autonomic dysfunction (AD). The aim of this study was to investigate cardiac and sudomotor autonomic function in subjects with PsO and without diabetes.
Methods:
A cross-sectional study was performed in 20 subjects with PsO, compared with age- and sex-matched 21 healthy controls, and 20 subjects with MetS. Subjects underwent skin evaluation by dermatologist, glycated hemoglobin (HbA1c), insulin, glucose, and lipid levels, sudomotor function testing with Sudoscan™ device (Impeto Medical, Paris, France), and cardiac autonomic function testing with ANSAR device (ANX 3.0; ANSAR Group, Inc., Philadelphia, PA). Quality of Life (QOL) and peripheral neurologic function were also assessed.
Results:
Participants with PsO were significantly more obese, had higher levels of fasting insulin and triglycerides, and were more insulin resistant when compared to controls. Subjects with PsO showed significantly worse cardiac autonomic function when compared to control and MetS groups. Sudomotor function and QOL scores were similar between the groups. Subgroup analysis of PsO subjects without MetS criteria (n = 15) showed persistent significantly deteriorated cardiac autonomic function when compared to the other two groups.
Conclusion:
This study suggests an association between PsO and cardiac AD, independent of the presence of overt dysglycemia and MetS. Additional larger studies are needed to clarify the significance of these findings and the relationship between PsO, AD, and metabolic disease.
Get full access to this article
View all access options for this article.
References
1.
RachakondaTD, SchuppCW, ArmstrongAW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol, 2014; 70:512–516.
2.
Edson-HerediaE, ZhuB, GuoJ, et al.Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: Results from National Psoriasis Foundation panel surveys. Cutis, 2015; 95:173–178.
3.
MillerIM, EllervikC, YazdanyarS, et al.Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol, 2013; 69:1014–1024.
4.
ArmstrongAW, HarskampCT, DhillonJS, et al.Psoriasis and smoking: A systematic review and meta-analysis. Br J Dermatol, 2014; 170:304–314.
5.
FlemingP, KraftJ, GulliverWP, et al.The relationship of obesity with the severity of psoriasis: A systematic review. J Cutan Med Surg, 2015; 19:450–456.
6.
ArmstrongAW, HarskampCT, ArmstrongEJ. Psoriasis and the risk of diabetes mellitus: A systematic review and meta-analysis. JAMA Dermatol, 2013; 149:84–91.
7.
VinikAI, NevoretML, CaselliniCM. The new age of sudomotor function testing: A sensitive and specific biomarker for diagnosis, estimation of severity, monitoring progression, and regression in response to intervention. Front Endocrinol, 2015; 6:94.
8.
SpalloneV, BellavereF, SciontiL, et al.Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovasc Dis, 2011; 21:69–78.
LiebDC, ParsonHK, MamikunianG, et al.Cardiac autonomic imbalance in newly diagnosed and established diabetes is associated with markers of adipose tissue inflammation. Exp Diabetes Res, 2012; 2012:878760.
11.
SyngleA, VermaI, GargN, et al.Autonomic dysfunction in psoriatic arthritis. Clin Rheumatol, 2013; 32:1059–1064.
12.
SyngleA, VermaI, KrishanP, et al.Disease-modifying antirheumatic drugs improve cardiovascular autonomic neuropathy in psoriatic arthritis. Ther Adv Musculoskelet Dis, 2016; 8:42–48.
13.
SingletonJR, BixbyB, RussellJW, et al.The Utah Early Neuropathy Scale: A sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Syst, 2008; 13:218–227.
14.
GibbonsCH, IlligensB, WanfN, et al.Quantification of sweat gland innervation: A clinical-pathologic correlation. Neurology, 2009; 72:1479–1486.
15.
IlligensBM, GibbonsCH. Sweat testing to evaluate autonomic function. Clin Auton Res, 2009; 19:79–87.
16.
VinikAI, NevoretM, CaselliniC, et al.Neurovascular function and sudorimetry in health and disease. Curr Diab Rep, 2013; 13:517–532.
17.
MayaudonH, MilochePO, BauduceauB.A new simple method for assessing sudomotor function: Relevance in type 2 diabetes. Diabetes Metab 2010;36:450–454.
18.
GinH, BaudoinR, RaffaitinCH, et al.Non-invasive and quantitative assessment of sudomotor function for peripheral diabetic neuropathy evaluation. Diabetes Metab, 2011; 37:527–532.
19.
CalvetJH, DupinJ, WinieckiH, et al.Assessment of small fiber neuropathy through a quick, simple and non invasive method in a German diabetes outpatient clinic. Exp Clin Endocrinol Diabetes, 2013; 2:80–83.
20.
RaisanenA, EklundJ, CalvetJH, et al.Sudomotor function as a tool for cardiorespiratory fitness level evaluation: Comparison with VO2 max. Int J Environ Res Public Health, 2014; 11:5839–5848.
21.
CaselliniCM, ParsonHK, RichardsonMS, et al.Sudoscan, a noninvasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction. Diabetes Technol Ther, 2013; 15:948–953.
22.
SmithAG, LessardM, ReynaS, et al.The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy. J Diabetes Complications, 2014; 28:511–516.
23.
FreedmanBI, SmithSC, BagwellBM, et al.Electrochemical skin conductance in diabetic kidney disease. Am J Nephrol, 2015; 41:438–447.
24.
SelvarajahD, CashT, DaviesJ, et al.SUDOSCAN: A simple, rapid, and objective method with potential for screening for diabetic peripheral neuropathy. PLos One, 2015; 10:e0138224.
25.
LukAO, FuWC, LiX, et al.The clinical utility of SUDOSCAN in chronic kidney disease in Chinese patients with type 2 diabetes. PLoS One, 2015; 10:e0134981.
26.
NovakP. Electrochemical skin conductance correlates with skin nerve fiber density. Front Aging Neurosci, 2016; 8:199.
27.
PorubcinMG, NovakP. Diagnostic accuracy of electrochemical skin conductance in the detection of sudomotor fiber loss. Front Neurol, 2020; 11:273.
28.
KriegerSM, ReimannM, HaaseR, et al.Sudomotor testing of diabetes polyneuropathy. Front Neurol, 2018; 9:803.
29.
VinikAI, SmithAG, SingletonJR, et al.Normative values for electrochemical skin conductances and impact of ethnicity on quantitative assessment of sudomotor function. Diabetes Technol Ther, 2016; 18:391–398.
30.
NovakP. Electrochemical skin conductance: A systematic review. Clin Auton Res, 2019; 29:17–29.
31.
CaselliniCM, ParsonHK, HodgesK, et al.Bariatric surgery restores cardiac and sudomotor autonomic C-fiber dysfunction towards normal in obese subjects with type 2 diabetes. PLoS One, 2016; 11:e0154211.
32.
NevoretML, VinikAI. CIDP variants in diabetes: Measuring treatment response with a small nerve fiber test. J Diabetes Complications, 2015; 29:313–317.
Heart rate variability: Standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation, 1996; 93:1043–1065.
35.
LevyJC, MatthewsDR, HermansMP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care, 1998; 21:2191–2192.
36.
VinikEJ, HayesRP, OglesbyA, et al.The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther, 2005; 7:497–508.
37.
VinikEJ, PaulsonJF, Ford-MolvikSL, et al.German-translated Norfolk quality of life (QOL-DN) identifies the same factors as the English version of the tool and discriminates different levels of neuropathy severity. J Diabetes Sci Technol, 2008; 2:1075–1086.
38.
BoydA, CasseliniCM, VinikEJ, et al.Quality of life and objective measures of diabetic neuropathy in a prospective placebo controlled trial of ruboxistaurin and topiramate. J Diabetes Sci Technol, 2011; 5:714–722.
39.
National Cholesterol Education Program (NCEP) Expert Panel onDetection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106;3143–3421.
40.
SettyG, ChoiHK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med, 2007; 167:1670–1675.
41.
SnekvikI, SmithCH, NilsenTIL, et al.Obesity, waist circumference, weight change, and risk of incident psoriasis: Prospective data from the HUNT Study. J Invest Dermatol, 2017; 137:2484–2490.
42.
MenterMA, AmstrongAW, GordonKB, et al.Common and not-so-common comorbidities of psoriasis. Semin Cutan Med Surg, 2018; 37:48–51.
43.
GreenbergRJ, GoldsmithT, ZeltserD, et al.Comorbidities in patients with palmoplantar plaque psoriasis. J Am Acad Dermatol, 2021; 84:639–643.
44.
GriffithsCEM, ArmstrongAW, GudjonssonJE, et al.Psoriasis. Lancet, 2021; 397:1301–1315.
ArmstrongAW, GuerinA, SundaramM, et al.Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. J Am Acad Dermatol, 2015; 72:968–977.
47.
YeungH, TakeshitaJ, MehtaN, et al.Psoriasis severity and the prevalence of major medical comorbidity: A population-based study. JAMA, 2013; 149:1173–1179.
48.
SchwandtA, BergisD, DappA, et al.Psoriasis and diabetes: A multicenter study in 222078 type 2 diabetes patients reveals high level of depression. J Diabetes Res, 2015; 2015:792968.
49.
PolicMV, MiskulinM, SmolicM, et al.Psoriasis severity—A risk factor of insulin resistance independent of metabolic syndrome. Int J Environ Res Public Health, 2018; 15:1486.
50.
UysalS, YilmazFM, KaratoprakK, et al.The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis. Eur Rev Med Pharmacol Sci, 2014; 18:3453–3458.
51.
DharaS, DasguptaA, RoutJK, et al.Clinico-biochemical correlation between psoriasis and insulin resistance. Indian J Clin Biochem, 2015; 30:99–103.
52.
GelfandJM, NeimannAL, ShinDB, et al.Risk of myocardial infarction in patients with psoriasis. JAMA, 2006; 296:1735–1741.
53.
GelfandJM, DommaschED, ShinDB, et al.The risk of stroke in patients with psoriasis. J Invest Dermatol, 2009; 29:2411–2418.
54.
ParisiR, RutterMK, LuntM, et al.Psoriasis and the risk of major cardiovascular event: Cohort study using the clinical practice research datalink. J Invest Dermatol, 2015; 135:2188–2197.
55.
ProiettiI, RaimondiG, SkrozaN, et al.Cardiovascular risk in psoriatic patients detected by heart rate variability (HRV) analysis. Drug Dev Res, 2014; 75:S81–S84.
56.
SpalloneV. Update on the impact, diagnosis and management of cardiovascular autonomic neuropathy in diabetes: What is defined, what is new, and what is unmet. Diabetic Med, 2019; 43:3–30.
57.
WilliamsS, EleftheriadouA, AlamU, et al.Cardiac autonomic neuropathy in obesity, the metabolic syndrome and prediabetes: A narrative review. Diabetes Ther, 2019; 10:1995–2021.
58.
ElnabawiY, DeyAK, GoyalA, et al.Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: Results from a prospective observational study. Cardiovasc Res, 2019; 115:721–728.
59.
YamazakiF, TakehanaK, TamashimaM, et al.Improvement in abnormal coronary arteries estimated by coronary computed tomography after secukinumab treatment in a Japanese psoriatic patient. J Dermatol, 2018; 46:e51–e52.
60.
AvgerinouG, TousoulisD, SiasosG, et al.Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. Int J Cardiol, 2011; 151:383.
61.
von StebutE, ReichK, ThaciD, et al.Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol, 2019; 139:1054–1062.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
